EGFR and lung carcinoma: In advanced NSCLC tumors of adenocarcinoma histology, current guidelines from the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC) and the Association of Molecular Pathologists (AMP) recommend EGFR analysis regardless of clinical characteristics [6], where these should not be used to either select or exclude patients for EGFR mutation testing, including ALK or ROS1 rearrangements.